Context Therapeutics® to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 06 2022 - 7:30AM
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq:
CNTX), a women’s oncology company developing novel treatments for
breast and gynecological cancers, today announced that Chief
Executive Officer Martin Lehr will participate in a fireside chat
during the H.C. Wainwright 24th Annual Global Investment Conference
taking place virtually and in-person September 12-14, 2022, in New
York City. The fireside chat will be available on demand for
conference participants beginning September 12 at 7 a.m. ET.
The Company will be available in-person in New York City to
participate in one-on-one meetings in conjunction with the
conference. Details about the conference can be found here:
https://hcwevents.com/annualconference/.
About Context
Therapeutics®Context Therapeutics Inc.
(Nasdaq: CNTX) is a clinical-stage biopharmaceutical company
committed to advancing medicines for female cancers. The Company’s
pipeline includes small molecule and bispecific antibody drug
candidates that target cancer signaling pathways. Onapristone
extended release (ONA-XR), a novel, first-in-class potent and
selective progesterone receptor antagonist, is currently in three
Phase 2 trials and one Phase 1b/2 trial in hormone-driven
breast, ovarian, and endometrial cancers. Context and The Menarini
Group (Menarini) have also entered a Clinical Trial Collaboration
and Supply Agreement for a Phase 1b/2 clinical proof-of-concept
trial evaluating ONA-XR in combination with Menarini’s oral
selective estrogen receptor degrader (SERD), elacestrant. Context
is also developing a selective Claudin 6 (CLDN6) x CD3 bispecific
antibody for CLDN6 positive tumors, currently in preclinical
development. Context is headquartered in Philadelphia. For
more information, please
visit www.contexttherapeutics.com or follow the Company
on Twitter and LinkedIn.
Forward-looking StatementsThis press release
contains “forward-looking statements” that involve substantial
risks and uncertainties for purposes of the safe harbor provided by
the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, included in
this press release regarding strategy, future operations,
prospects, plans and objectives of management, including words such
as "may," "will," "expect," "anticipate," "plan," "intend," and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
forward-looking statements. These include, without limitation,
statements regarding (i) the ability of the Company and its
employees to participate in and present at conferences, (ii) the
results of our clinical trials, (iii) the potential benefits of the
product candidates, (iv) the likelihood data will support future
development, and (v) the likelihood of obtaining regulatory
approval of our product candidates. Forward-looking statements in
this release involve substantial risks and uncertainties that could
cause actual results to differ materially from those expressed or
implied by the forward-looking statements, and we, therefore cannot
assure you that our plans, intentions, expectations or strategies
will be attained or achieved. Other factors that may cause actual
results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
our filings with the U.S. Securities and Exchange Commission,
including the section titled “Risk Factors” contained therein.
Except as otherwise required by law, we disclaim any intention or
obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result
of new information, future events or circumstances or
otherwise.
Media Contact:Gina Cestari6
Degrees917-797-7904gcestari@6degreespr.com
Investor Relations Contact:Laine YonkerEdison
Grouplyonker@edisongroup.com
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Apr 2023 to Apr 2024